The long-term course of low-density lipoprotein cholesterol after initiation of statin treatment: Retrospective database analysis over 3 years in health maintenance organization enrollees

Clinical Therapeutics

Volumn 27, Issue 10, 2005, Pages 1622-1628

  Caspard, Herve ^a   Chan, Arnold K ^b   Walker, Alexander M ^b,c  

^a SANOFI   (France)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^c I3 Magnifi/Ingenix Epidemiology ^*  (United States)

Author keywords

LDL cholesterol; Statin; Usual care

Indexed keywords

FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PRAVASTATIN;

ADULT; AGED; ARTICLE; CALCULATION; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DATA BASE; DEMOGRAPHY; DRUG EFFECT; DRUG WITHDRAWAL; FEMALE; HEALTH CARE; HEALTH MAINTENANCE ORGANIZATION; HUMAN; MALE; PHYSICIAN; PREDICTION; PRESCRIPTION; RETROSPECTIVE STUDY; SAMPLING;

AGED; ANTICHOLESTEREMIC AGENTS; CHOLESTEROL, LDL; DATA INTERPRETATION, STATISTICAL; FATTY ACIDS, MONOUNSATURATED; FEMALE; HEALTH MAINTENANCE ORGANIZATIONS; HUMANS; HYPERLIPIDEMIAS; INDOLES; LONG-TERM CARE; MALE; MIDDLE AGED; PRAVASTATIN; RETROSPECTIVE STUDIES; TIME FACTORS;

EID: 28444439831     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2005.09.004     Document Type: Article

References (19)

1. Braunstein J.B., Cheng A., and Cohn G. Lipid disorders: Justification of methods and goals of treatment Chest 120 2001 979 988
2. Heart Protection Study Collaborative Group MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,356 high-risk individuals: A randomised placebo-controlled trial Lancet 360 2002 7 22
3. Available at: American Stroke Association, American Heart Association Heart Diseases and Stroke Statistics - 2005 Update Accessed August 24 2005
4. Hebert P.R., Gaziano J.M., Chan K.S., and Hennekens C.H. Cholesterol lowering with statin drugs, risk of stroke, and total mortality. An overview of randomized trials JAMA 278 1997 313 321
5. LaRosa J.C., He J., and Vupputuri S. Effect of statins on risk of coronary disease: A meta-analysis of randomized controlled trials JAMA 282 1999 2340 2346
6. Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation and Treatment ofHigh Blood Cholesterol in Adults (Adult Treatment Panel III) JAMA 285 2001 2486 2497
7. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S) Lancet 344 1994 1383 1389
8. Shepherd J., Cobbe S.M., Ford I. West of Scotland Coronary Prevention Study Group Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia N Engl J Med 333 1995 1301 1307
9. Sacks F.M., Pfeffer M.A., and Moye L.A. Cholesterol and Recurrent Events Trial Investigators The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels N Engl J Med 335 1996 1001 1009
10. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterollevels N Engl J Med 339 1998 1349 1357
11. Downs J.R., Clearfield M., and Weis S. Air Force/Texas Coronary Atherosclerosis Prevention Study Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: Results of AFCAPS/TexCAPS JAMA 279 1998 1615 1622
12. Gould A.L., Rossouw J.E., and Santanello N.C. Cholesterol reduction yields clinical benefit: Impact of statin trials Circulation 97 1998 946 952
13. Frolkis J.P., Pearce G.L., and Nambi V. Statins do not meet expectations for lowering low-density lipoprotein cho lesterol levels when used in clinical practice Am J Med 113 2002 625 629
14. Pearson T.A., Laurora I., Chu H., and Kafonek S. The lipid treatment assessment project (L-TAP): A multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipid-lowering therapy and achieving low-density lipoprotein cholesterol goals Arch Intern Med 160 2000 459 467
15. Sacks F.M. Adherence to statin therapy: Why aren't we doing better? Am J Med 113 2002 685 686
16. Seeger J.D., Walker A.M., and Williams P.L. A propensity score-matched cohort study of the effect of statins, mainly fluvastatin, on the occurrence of acute myocardial infarction Am J Cardiol 92 2003 1447 1451
17. Cnaan A.A., Laird N.M., and Slasor P. Using the general linear mixed model to analyse unbalanced repeated measures and longitudinal data Stat Med 16 1997 2349 2380
18. Chong P.H., Seeger J.D., and Franklin C. Clinically relevant differences between the statins: Implications for therapeutic selection Am J Med 111 2001 390 400
19. Avorn J., Monette J., and Lacour A. Persistence of use of lipid lowering medications: A cross-national study JAMA 279 1998 1458 1462